BCR-ABL1—Negative Myeloproliferative Neoplasms: A Review of Molecular Biology, Diagnosis, and Treatment
- 1 June 2011
- journal article
- review article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 11, S37-S45
- https://doi.org/10.1016/j.clml.2011.04.002
Abstract
No abstract availableThis publication has 99 references indexed in Scilit:
- IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosisLeukemia, 2010
- Outcome of Transplantation for MyelofibrosisTransplantation and Cellular Therapy, 2010
- Mutation in TET2 in Myeloid CancersThe New England Journal of Medicine, 2009
- A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasmsNature Genetics, 2009
- Evidence and expertise in the management of polycythemia vera and essential thrombocythemiaLeukemia, 2008
- Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosisBlood, 2007
- JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic ErythrocytosisThe New England Journal of Medicine, 2007
- The haematocrit and platelet target in polycythemia veraBritish Journal of Haematology, 2006
- Hydroxyurea Compared with Anagrelide in High-Risk Essential ThrombocythemiaThe New England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005